Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of JKN2403 in moderate to severe COPD
CTR20253078Phase 2Active
- Sponsor
- Joincare Pharmaceutical
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JKN2403 in chronic obstructive pulmonary disease (COPD), sponsored by Joincare Pharmaceutical. Started Nov 2025; status: active.
02
Drugs
JKN2403
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20253078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253078.